BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Meng XC, Chen BH, Huang JJ, Huang WS, Cai MY, Zhou JW, Guo YJ, Zhu KS. Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib. World J Gastroenterol 2018; 24(4): 484-493 [PMID: 29398869 DOI: 10.3748/wjg.v24.i4.484]
URL: https://www.wjgnet.com/1948-5182/full/v24/i4/484.htm
Number Citing Articles
1
Shuguang Ju, Chen Zhou, Junwen Hu, Yingliang Wang, Chaoyang Wang, Jiacheng Liu, Chongtu Yang, Songjiang Huang, Tongqiang Li, Yang Chen, Yaowei Bai, Wei Yao, Bin Xiong. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combinationBMC Cancer 2022; 22(1) doi: 10.1186/s12885-022-09451-1
2
Zi-Wen Tao, Bao-Quan Cheng, Tao Zhou, Yan-Jing Gao. Management of hepatocellular carcinoma patients with portal vein tumor thrombosis: A narrative reviewHepatobiliary & Pancreatic Diseases International 2022; 21(2): 134 doi: 10.1016/j.hbpd.2021.12.004
3
He An, Inderjeet Bhatia, Fei Cao, Zilin Huang, Chuanmiao Xie. CT texture analysis in predicting treatment response and survival in patients with hepatocellular carcinoma treated with transarterial chemoembolization using random forest modelsBMC Cancer 2023; 23(1) doi: 10.1186/s12885-023-10620-z
4
Krzysztof Bartnik, Joanna Podgórska, Grzegorz Rosiak, Krzysztof Korzeniowski, Jakub Giziński, Michał Sajdek, Tadeusz Wróblewski, Krzysztof Zieniewicz, Paweł Nyckowski, Olgierd Rowiński. Performance of initial LI-RADS 2018 treatment response in predicting survival of patients with hepatocellular carcinoma following TACE: a retrospective, single-center cohort studyJournal of Cancer Research and Clinical Oncology 2021; 147(12): 3673 doi: 10.1007/s00432-021-03603-9